Furthermore, the dual tumor-associated antigen targeting improves therapeutic specificity by preferentially eliminating CD117+CD33+ cells, possibly allowing improved bispecific antibody-mediated AML therapy. This evidence concerns the gene KIT and acute myeloid leukemia.